VIPhyb, an Antagonist of Vasoactive Intestinal Peptide Receptor, Enhances Cellular Antiviral Immunity in Murine Cytomegalovirus Infected Mice
Figure 1
Blocking VIP-signaling did not change the numbers of immune cells.
VIP-KO (open bar) mice or WT mice treated with a short-course of VIPhyb (10 µg/mouse s.c., gray filled bar) or PBS (100 µL/mouse s.c., black filled bar) (n = 5–10 per group each experiment) were euthanized one day after the last dose of administration, the spleens, femurs and tibias were isolated. Hematopoietic cells harvested from the spleens and bones were phenotyped by flow cytometry. Data (mean ± SD, n = 25) are summarized from 3 replicate experiments. A–C: Lymphocyte subsets from BM. D–I: Lymphocyte subsets from spleen. J–L: DC subsets from spleen. Data shown on panel L are mean values (SD were 20–30% of the mean values, and not shown for the sake of clarity in the panel).